Table of Content

1. Preface
????1.1. Market Definition and Scope
????1.2. Market Segmentation
????1.3. Key Research Objectives
????1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Companion Diagnostic Tests in Oncology Market

4. Market Overview
????4.1. Introduction
????????4.1.1. Product Definition
????????4.1.2. Industry Evolution / Developments
????4.2. Overview
????4.3. Market Dynamics
????????4.3.1. Drivers
????????4.3.2. Restraints
????????4.3.3. Opportunities
????4.4. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, 2020 - 2034

5. Key Insights
????5.1. Pipeline Analysis
????5.2. Key Product/Brand Analysis
????5.3. Key Mergers & Acquisitions
????5.4. COVID-19 Pandemic Impact on Industry

6. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Detection Technique
????6.1. Introduction and Definitions
????6.2. Key Findings/Developments
????6.3. Market Value Forecast, by Detection Technique, 2020 - 2034
????????6.3.1. Protein Detection
????????????6.3.1.1. Immunohistochemistry
????????6.3.2. DNA Detection
????????????6.3.2.1. Polymerase Chain Reaction (PCR)
????????????6.3.2.2. Next-generation Sequencing (NGS)
????????????6.3.2.3. In Situ Hybridization
????????6.3.3. Others
????6.4. Market Attractiveness, by Detection Technique

7. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Biomarker
????7.1. Introduction and Definitions
????7.2. Key Findings/Developments
????7.3. Market Value Forecast, by Biomarker, 2020 - 2034
????????7.3.1. EGFR
????????7.3.2. KRAS
????????7.3.3. HER2
????????7.3.4. BRAF V600E
????????7.3.5. Others
????????7.3.6. 7.4 Market Attractiveness, by Biomarker

8. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Cancer Type
????8.1. Introduction and Definitions
????8.2. Key Findings/Developments
????8.3. Market Value Forecast, by Cancer Type, 2020 - 2034
????????8.3.1. Breast Cancer
????????8.3.2. Lung Cancer
????????8.3.3. Colorectal Cancer
????????8.3.4. Liver Cancer
????????8.3.5. Melanoma
????????8.3.6. Others
????8.4. Market Attractiveness, by Cancer Type

9. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by End-user
????9.1. Introduction and Definitions
????9.2. Key Findings/Developments
????9.3. Market Value Forecast, by End-user, 2020 - 2034
????????9.3.1. Hospitals
????????9.3.2. Specialty Clinics
????????9.3.3. Diagnostic Labs
????????9.3.4. Others
????9.4. Market Attractiveness, by End-user

10. Global Companion Diagnostic Tests in Oncology Market Analysis and Forecast, by Region
????10.1. Key Findings
????10.2. Market Value Forecast, by Region, 2020 - 2034
????????10.2.1. North America
????????10.2.2. Europe
????????10.2.3. Asia Pacific
????????10.2.4. Latin America
????????10.2.5. Middle East & Africa
????10.3. Market Attractiveness, by Region

11. North America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
????11.1. Introduction
????????11.1.1. Key Findings
????11.2. Market Value Forecast, by Detection Technique, 2020 - 2034
????????11.2.1. Protein Detection
????????????11.2.1.1. Immunohistochemistry
????????11.2.2. DNA Detection
????????????11.2.2.1. Polymerase Chain Reaction (PCR)
????????????11.2.2.2. Next-generation Sequencing (NGS)
????????????11.2.2.3. In Situ Hybridization
????????11.2.3. Others
????11.3. Market Attractiveness, by Detection Technique
????11.4. Market Value Forecast, by Biomarker, 2020 - 2034
????????11.4.1. EGFR
????????11.4.2. KRAS
????????11.4.3. HER2
????????11.4.4. BRAF V600E
????????11.4.5. Others
????11.5. Market Attractiveness, by Biomarker
????11.6. Market Value Forecast, by Cancer Type, 2020 - 2034
????????11.6.1. Breast Cancer
????????11.6.2. Lung Cancer
????????11.6.3. Colorectal Cancer
????????11.6.4. Liver Cancer
????????11.6.5. Melanoma
????????11.6.6. Others
????11.7. Market Attractiveness, by Cancer Type
????11.8. Market Value Forecast, by End-user, 2020 - 2034
????????11.8.1. Hospitals
????????11.8.2. Specialty Clinics
????????11.8.3. Diagnostic Labs
????????11.8.4. Others
????11.9. Market Attractiveness, by End-user
????11.10. Market Value Forecast, by Country, 2020 - 2034
????????11.10.1. U.S.
????????11.10.2. Canada
????11.11. Market Attractiveness Analysis
????????11.11.1. By Detection Technique
????????11.11.2. By Biomarker
????????11.11.3. By Cancer Type
????????11.11.4. By End-user
????????11.11.5. By Country

12. Europe Companion Diagnostic Tests in Oncology Market Analysis and Forecast
????12.1. Introduction
????????12.1.1. Key Findings
????12.2. Market Value Forecast, by Detection Technique, 2020 - 2034
????????12.2.1. Protein Detection
????????????12.2.1.1. Immunohistochemistry
????????12.2.2. DNA Detection
????????????12.2.2.1. Polymerase Chain Reaction (PCR)
????????????12.2.2.2. Next-generation Sequencing (NGS)
????????????12.2.2.3. In Situ Hybridization
????????12.2.3. Others
????12.3. Market Attractiveness, by Detection Technique
????12.4. Market Value Forecast, by Biomarker, 2020 - 2034
????????12.4.1. EGFR
????????12.4.2. KRAS
????????12.4.3. HER2
????????12.4.4. BRAF V600E
????????12.4.5. Others
????12.5. Market Attractiveness, by Biomarker
????12.6. Market Value Forecast, by Cancer Type, 2020 - 2034
????????12.6.1. Breast Cancer
????????12.6.2. Lung Cancer
????????12.6.3. Colorectal Cancer
????????12.6.4. Liver Cancer
????????12.6.5. Melanoma
????????12.6.6. Others
????12.7. Market Attractiveness, by Cancer Type
????12.8. Market Value Forecast, by End-user, 2020 - 2034
????????12.8.1. Hospitals
????????12.8.2. Specialty Clinics
????????12.8.3. Diagnostic Labs
????????12.8.4. Others
????12.9. Market Attractiveness, by End-user
????12.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
????????12.10.1. Germany
????????12.10.2. U.K.
????????12.10.3. France
????????12.10.4. Italy
????????12.10.5. Spain
????????12.10.6. Rest of Europe
????12.11. Market Attractiveness Analysis
????????12.11.1. By Detection Technique
????????12.11.2. By Biomarker
????????12.11.3. By Cancer Type
????????12.11.4. By End-user
????????12.11.5. By Country/Sub-region

13. Asia Pacific Companion Diagnostic Tests in Oncology Market Analysis and Forecast
????13.1. Introduction
????????13.1.1. Key Findings
????13.2. Market Value Forecast, by Detection Technique, 2020 - 2034
????????13.2.1. Protein Detection
????????????13.2.1.1. Immunohistochemistry
????????13.2.2. DNA Detection
????????????13.2.2.1. Polymerase Chain Reaction (PCR)
????????????13.2.2.2. Next-generation Sequencing (NGS)
????????????13.2.2.3. In Situ Hybridization
????????13.2.3. Others
????13.3. Market Attractiveness, by Detection Technique
????13.4. Market Value Forecast, by Biomarker, 2020 - 2034
????????13.4.1. EGFR
????????13.4.2. KRAS
????????13.4.3. HER2
????????13.4.4. BRAF V600E
????????13.4.5. Others
????13.5. Market Attractiveness, by Biomarker
????13.6. Market Value Forecast, by Cancer Type, 2020 - 2034
????????13.6.1. Breast Cancer
????????13.6.2. Lung Cancer
????????13.6.3. Colorectal Cancer
????????13.6.4. Liver Cancer
????????13.6.5. Melanoma
????????13.6.6. Others
????13.7. Market Attractiveness, by Cancer Type
????13.8. Market Value Forecast, by End-user, 2020 - 2034
????????13.8.1. Hospitals
????????13.8.2. Specialty Clinics
????????13.8.3. Diagnostic Labs
????????13.8.4. Others
????13.9. Market Attractiveness, by End-user
????13.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
????????13.10.1. China
????????13.10.2. Japan
????????13.10.3. India
????????13.10.4. Australia & New Zealand
????????13.10.5. Rest of Asia Pacific
????13.11. Market Attractiveness Analysis
????????13.11.1. By Detection Technique
????????13.11.2. By Biomarker
????????13.11.3. By Cancer Type
????????13.11.4. By End-user
????????13.11.5. By Country/Sub-region
14. Latin America Companion Diagnostic Tests in Oncology Market Analysis and Forecast
????14.1. Introduction
????????14.1.1. Key Findings
????14.2. Market Value Forecast, by Detection Technique, 2020 - 2034
????????14.2.1. Protein Detection
????????????14.2.1.1. Immunohistochemistry
????????14.2.2. DNA Detection
????????????14.2.2.1. Polymerase Chain Reaction (PCR)
????????????14.2.2.2. Next-generation Sequencing (NGS)
????????????14.2.2.3. In Situ Hybridization
????????14.2.3. Others
????14.3. Market Attractiveness, by Detection Technique
????14.4. Market Value Forecast, by Biomarker, 2020 - 2034
????????14.4.1. EGFR
????????14.4.2. KRAS
????????14.4.3. HER2
????????14.4.4. BRAF V600E
????????14.4.5. Others
????14.5. Market Attractiveness, by Biomarker
????14.6. Market Value Forecast, by Cancer Type, 2020 - 2034
????????14.6.1. Breast Cancer
????????14.6.2. Lung Cancer
????????14.6.3. Colorectal Cancer
????????14.6.4. Liver Cancer
????????14.6.5. Melanoma
????????14.6.6. Others
????14.7. Market Attractiveness, by Cancer Type
????14.8. Market Value Forecast, by End-user, 2020 - 2034
????????14.8.1. Hospitals
????????14.8.2. Specialty Clinics
????????14.8.3. Diagnostic Labs
????????14.8.4. Others
????14.9. Market Attractiveness, by End-user
????14.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
????????14.10.1. Brazil
????????14.10.2. Mexico
????????14.10.3. Rest of Latin America
????14.11. Market Attractiveness Analysis
????????14.11.1. By Detection Technique
????????14.11.2. By Biomarker
????????14.11.3. By Cancer Type
????????14.11.4. By End-user
????????14.11.5. By Country/Sub-region

15. Middle East & Africa Companion Diagnostic Tests in Oncology Market Analysis and Forecast
????15.1. Introduction
????????15.1.1. Key Findings
????15.2. Market Value Forecast, by Detection Technique, 2020 - 2034
????????15.2.1. Protein Detection
????????????15.2.1.1. Immunohistochemistry
????????15.2.2. DNA Detection
????????????15.2.2.1. Polymerase Chain Reaction (PCR)
????????????15.2.2.2. Next-generation Sequencing (NGS)
????????????15.2.2.3. In Situ Hybridization
????????15.2.3. Others
????15.3. Market Attractiveness, by Detection Technique
????15.4. Market Value Forecast, by Biomarker, 2020 - 2034
????????15.4.1. EGFR
????????15.4.2. KRAS
????????15.4.3. HER2
????????15.4.4. BRAF V600E
????????15.4.5. Others
????15.5. Market Attractiveness, by Biomarker
????15.6. Market Value Forecast, by Cancer Type, 2020 - 2034
????????15.6.1. Breast Cancer
????????15.6.2. Lung Cancer
????????15.6.3. Colorectal Cancer
????????15.6.4. Liver Cancer
????????15.6.5. Melanoma
????????15.6.6. Others
????15.7. Market Attractiveness, by Cancer Type
????15.8. Market Value Forecast, by End-user, 2020 - 2034
????????15.8.1. Hospitals
????????15.8.2. Specialty Clinics
????????15.8.3. Diagnostic Labs
????????15.8.4. Others
????15.9. Market Attractiveness, by End-user
????15.10. Market Value Forecast, by Country/Sub-region, 2020 - 2034
????????15.10.1. GCC Countries
????????15.10.2. South Africa
????????15.10.3. Rest of Middle East & Africa
????15.11. Market Attractiveness Analysis
????????15.11.1. By Detection Technique
????????15.11.2. By Biomarker
????????15.11.3. By Cancer Type
????????15.11.4. By End-user
????????15.11.5. By Country/Sub-region

16. Competition Landscape
????16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
????16.2. Market Share Analysis, by Company (2023)
????16.3. Company Profiles
????????16.3.1. Abbott
????????????16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.1.2. Product Portfolio
????????????16.3.1.3. Financial Overview
????????????16.3.1.4. SWOT Analysis
????????????16.3.1.5. Strategic Overview
????????16.3.2. F. Hoffmann-LA Roche AG
????????????16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.2.2. Product Portfolio
????????????16.3.2.3. Financial Overview
????????????16.3.2.4. SWOT Analysis
????????????16.3.2.5. Strategic Overview
????????16.3.3. Genomic Health, Inc.
????????????16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.3.2. Product Portfolio
????????????16.3.3.3. Financial Overview
????????????16.3.3.4. SWOT Analysis
????????????16.3.3.5. Strategic Overview
????????16.3.4. QIAGEN
????????????16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.4.2. Product Portfolio
????????????16.3.4.3. Financial Overview
????????????16.3.4.4. SWOT Analysis
????????????16.3.4.5. Strategic Overview
????????16.3.5. Agilent Technologies, Inc.
????????????16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.5.2. Product Portfolio
????????????16.3.5.3. Financial Overview
????????????16.3.5.4. SWOT Analysis
????????????16.3.5.5. Strategic Overview
????????16.3.6. AGENDIA N.V.
????????????16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.6.2. Product Portfolio
????????????16.3.6.3. Financial Overview
????????????16.3.6.4. SWOT Analysis
????????????16.3.6.5. Strategic Overview
????????16.3.7. bioM?rieux SA
????????????16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.7.2. Product Portfolio
????????????16.3.7.3. Financial Overview
????????????16.3.7.4. SWOT Analysis
????????????16.3.7.5. Strategic Overview
????????16.3.8. Illumina, Inc.
????????????16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.8.2. Product Portfolio
????????????16.3.8.3. Financial Overview
????????????16.3.8.4. SWOT Analysis
????????????16.3.8.5. Strategic Overview
????????16.3.9. Siemens Healthineers
????????????16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.9.2. Product Portfolio
????????????16.3.9.3. Financial Overview
????????????16.3.9.4. SWOT Analysis
????????????16.3.9.5. Strategic Overview
????????16.3.10. Thermo Fisher Scientific Inc.
????????????16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.10.2. Product Portfolio
????????????16.3.10.3. Financial Overview
????????????16.3.10.4. SWOT Analysis
????????????16.3.10.5. Strategic Overview
????????16.3.11. BioGenex
????????????16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
????????????16.3.11.2. Product Portfolio
????????????16.3.11.3. Financial Overview
????????????16.3.11.4. SWOT Analysis
????????????16.3.11.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million), by Region, 2023 - 2034

Figure 02: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Detection Technique, 2023

Figure 03: Global Companion Diagnostic Tests in Oncology Market Value Share, by Detection Technique, 2023

Figure 04: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Biomarker, 2023

Figure 05: Global Companion Diagnostic Tests in Oncology Market Value Share, by Biomarker, 2023

Figure 06: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by Cancer Type, 2023

Figure 07: Global Companion Diagnostic Tests in Oncology Market Value Share, by Cancer Type, 2023

Figure 08: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023

Figure 09: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023

Figure 10: Global Companion Diagnostic Tests in Oncology Market Value Share, by Region, 2023

Figure 11: Global Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast, 2020 - 2034

Figure 12: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

Figure 13: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

Figure 14: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

Figure 15: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

Figure 16: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

Figure 17: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

Figure 18: Global Companion Diagnostic Tests in Oncology Market Revenue (US$ Million), by End-user, 2023

Figure 19: Global Companion Diagnostic Tests in Oncology Market Value Share, by End-user, 2023

Figure 20: Global Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Region, 2023 - 2034

Figure 21: Global Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Region, 2024 - 2034

Figure 22: North America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

Figure 23: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country, 2024 - 2034

Figure 24: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country, 2023 - 2034

Figure 25: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

Figure 26: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

Figure 27: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

Figure 28: North America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

Figure 29: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

Figure 30: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

Figure 31: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

Figure 32: North America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034

Figure 33: Europe Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

Figure 34: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034

Figure 35: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034

Figure 36: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

Figure 37: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

Figure 38: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

Figure 39: Europe Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

Figure 40: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

Figure 41: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

Figure 42: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

Figure 43: Europe Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034

Figure 44: Asia Pacific Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

Figure 45: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034

Figure 46: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034

Figure 47: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

Figure 48: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

Figure 49: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

Figure 50: Asia Pacific Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

Figure 51: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

Figure 52: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

Figure 53: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

Figure 54: Asia Pacific Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2023–2034

Figure 55: Latin America Companion Diagnostic Tests in Oncology Market Value (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

Figure 56: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034

Figure 57: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034

Figure 58: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

Figure 59: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

Figure 60: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

Figure 61: Latin America Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

Figure 62: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

Figure 63: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

Figure 64: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

Figure 65: Latin America Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034

Figure 66: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast and Y-o-Y Growth (%), 2020 - 2034

Figure 67: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Country/Sub-region, 2024 - 2034

Figure 68: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Country/Sub-region, 2023 - 2034

Figure 69: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Detection Technique, 2023 - 2034

Figure 70: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Biomarker, 2023 - 2034

Figure 71: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by Cancer Type, 2023 - 2034

Figure 72: Middle East & Africa Companion Diagnostic Tests in Oncology Market Value Share Analysis, by End-user, 2023 - 2034

Figure 73: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Detection Technique, 2024 - 2034

Figure 74: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Biomarker, 2024 - 2034

Figure 75: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by Cancer Type, 2024 - 2034

Figure 76: Middle East & Africa Companion Diagnostic Tests in Oncology Market Attractiveness Analysis, by End-user, 2024 - 2034

List of Tables

List of Tables

Table 01: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

Table 02: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

Table 03: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

Table 04: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

Table 05: Global Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Region, 2020 - 2034

Table 06: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country, 2020 - 2034

Table 07: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

Table 08: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

Table 9: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

Table 10: North America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

Table 11: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034

Table 12: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

Table 13: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

Table 14: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

Table 15: Europe Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

Table 16: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034

Table 17: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

Table 18: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

Table 19: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

Table 20: Asia Pacific Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

Table 21: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034

Table 22: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

Table 23: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

Table 24: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

Table 25: Latin America Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034

Table 26: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Country/Sub-region, 2020 - 2034

Table 27: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Detection Technique, 2020 - 2034

Table 28: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Biomarker, 2020 - 2034

Table 29: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by Cancer Type, 2020 - 2034

Table 30: Middle East & Africa Companion Diagnostic Tests in Oncology Market Size (US$ Million) Forecast, by End-user, 2020 - 2034